International pharmaceutical firm Angelini Pharma has initiated a creative crowdsourcing campaign aimed at enhancing target identification in epilepsy, particularly focusing on drug-resistant phenotypes.
Evotec’s end-to-end integrated research and development platform will be able to advance drug discovery for two drug targets which is why it has joined forces with the Crohn’s & Colitis Foundation.
The latest Study Voices survey from BBK Worldwide indicates healthcare consumers and trial participants think alike towards technology, doctor access and quality of care.
